Chardan lowered the firm’s price target on Cognition Therapeutics (CGTX) to $8 from $11 and keeps a Buy rating on the shares after the company reported FY24 financial results and provided updates on its programs. Following “promising” data from Phase 2 studies of zervimesine in Alzheimer’s disease and dementia with Lewy bodies, Cognition will request end of Phase 2 meetings with the FDA to align on plans for Phase 3, the analyst noted.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX: